Dr. Yusuf Hamied, head of the Indian pharmaceutical and generic drug manufacturing company Cipla is to continue to support weighing options for the global fight against HIV / AIDS, while positioning his company for growth in a changing regulatory environment .

Dr. Yusuf Hamied, head of the Indian pharmaceutical and generic drug manufacturing company Cipla is to continue to support weighing options for the global fight against HIV / AIDS, while positioning his company for growth in a changing regulatory environment .
«Hide

from
Rohit Deshpande,
Sandra J. viewfinder
Laura Winig
Source: Harvard Business School
26 pages.
Release Date: 12 April 2011. Prod #: 511050-PDF-ENG
Cipla 2011 HBR case solution